|
Endocrine and Metabolic Studies
Utilize PPD’s specialized therapeutic expertise and study experience
to manage multinational clinical trials for a broad range of endocrine and metabolic
indications and therapies. We provide expert resources around the
world for efficient and cost-conscious drug development — from the assembly
of clinical trial applications through multinational regulatory approval and
post-approval positioning.
Expertise for Challenging Clinical Studies
A dedicated project team assigned to your study ensures continuity for its duration.
We provide:
- Expertise based on a broad range of endocrine and metabolic disorder/clinical
studies
- Global experience, supported by automated query resolution
- Expedited patient and investigator recruitment
- Multinational regulatory expertise
Rapid Access to Specialized Investigators
PPD has a versatile investigator database containing more than 22,000 investigators
worldwide as well as background and project-related performance data of sites
in use. More than 65 percent of these investigators have participated in a PPD-managed
trial, and many are experienced in conducting endocrinology clinical research
trials.
Experience with a Broad Range of Endocrine and Metabolic Studies
We effectively manage Phase I-IV multinational studies for our clients across
a broad range of indications and therapies:
- Diabetes mellitus
- Endocrine hypertension
- Growth factors
- Hormone replacement therapy
- Lipid disorders
- Obesity
- Osteoporosis
- Thyroid disorders
|
| II |
Hormone replacement and low libido |
21
|
220
|
Australia, France, Germany, Italy, The Netherlands, United Kingdom |
| II |
Hormone replacement and low libido |
26
|
160
|
Australia, France, Germany, Italy, The Netherlands, United Kingdom |
| III |
Diabetes mellitus and sexual dysfunction |
20
|
254
|
United States |
| III |
Diabetes mellitus and sexual dysfunction |
140
|
642
|
Austria, and Denmark, Germany, Israel, Norway, Poland, Russia, South Africa, United Kingdom |
| III |
Type 2 diabetes, pediatric |
50
|
48
|
United States |
| III |
Diabetes mellitus |
52
|
240
|
Belgium, Finland, Israel, South Africa, The Netherlands, United Kingdom |
| III |
Diabetes mellitus |
67
|
312
|
United States |
| III |
Type 2 diabetes, pediatric |
33
|
110
|
Poland, Russia, United States |
| III |
Type 2 diabetes, pediatric |
196
|
82
|
Belgium, The Netherlands, Sweden, United Kingdom |
| III |
Hirsutism |
8
|
101
|
Belgium, Denmark, Italy |
| III |
Osteoporosis, post menopausal |
4
|
474
|
France, Germany, Denmark, United Kingdom |
| III |
Osteoporosis, post menopausal |
12
|
300
|
United States |
| III |
Osteoporosis, population sampling |
4
|
832
|
United States |
| III |
Osteoporosis, post menopausal |
10
|
615
|
United States |
| III |
Osteoporosis, post menopausal |
10
|
149
|
United States |
| III |
Osteoporosis, post menopausal |
13
|
136
|
United States |
| III |
Osteoporosis, post menopausal |
1
|
58
|
United States |
| III |
Osteoporosis, post menopausal |
30
|
1,129
|
United States |
| III |
Osteoporosis, post menopausal |
38
|
998
|
United States |
| III |
Osteoporosis and hip fracture |
1
|
3,000
|
United States |
| III |
Obesity in hypertensives |
40
|
550
|
United States |
| III |
Obesity in diabetics |
41
|
536
|
United States |
| IV |
Obesity in diabetics |
34
|
296
|
United States |
| IV |
Hormone replacement |
5
|
384
|
United States |
| IV |
Hormone replacement |
12
|
150
|
United States |
| IV |
Hormone replacement |
5
|
220
|
United States |
Investigators by Indication
|
|